Teva UK Limited Comments on Department of Health Generic Substitution Outcome

CASTLEFORD, England, October 15, 2010 - Teva UK Limited, the UK's leading manufacturer of generic medicines, has
today commented on the Department of Health's (DH) decision not to implement
generic substitution in primary care.

Although deciding not to go ahead with generic substitution as the
original proposals stood, DH has indicated that it will be "looking at
further ways to support the use of generic medicines in a way that is
acceptable to patients, recognising that there are still some savings that
can potentially be delivered in this area".(1)

Says Richard Daniell, Commercial Operations Officer at Teva: "Teva is
fully supportive of DH's aim to increase access to affordable medicines by
encouraging cost-effective generic prescribing as an equivalent alternative
to branded prescribing where there is no clinical reason not to do so."

Generic medicines maintain the same standards of quality, safety and
efficacy as the originator brand at an average of 20% of the cost, and
deliver GBP8.6 billion of savings to the NHS each year.(2)

Adds Richard: "To continue to prescribe by brand where there is an
equivalent clinically proven and cost-effective alternative prevents NHS
funds being used in other ways. As the UK's leading manufacturer of generic
medicines, Teva would welcome the opportunity to work with DH to help
maximise generic contribution to the NHS and save the UK tax payer even
more."

To find out more about Teva, visit www.tevauk.com.

References:

(1) DH website
www.dh.gov.uk/en/Consultations/Responsestoconsultations/DH_120431 -14/10/10

(2) BGMA Press Release 14/10/2010

About Teva UK Limited

Teva UK Limited is one of the UK's top ten pharmaceutical manufacturers,
with a presence in the generics, branded respiratory and hospitals markets.
It has the widest range of any UK generic pharmaceutical company and markets
solid and liquid dose, injectable and respiratory medicines to healthcare
professionals. The company is part of Teva Pharmaceutical Industries Ltd.

About Teva Pharmaceutical Industries Ltd

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic drugs as
well as innovative and specialty pharmaceuticals and active pharmaceutical
ingredients. Headquartered in Israel, Teva is the world's largest generic
drug maker, with a global product portfolio of more than 1,250 molecules and
a direct presence in 59 countries.

Teva's branded businesses focus on neurological, respiratory and women's
health therapeutic areas as well as biologics. Teva's leading innovative
product, Copaxone(R), is the number one prescribed treatment for multiple
sclerosis. Teva employs over 40,000 people around the world and reached $13.9
billion in net sales in 2009.

For media enquiries, contact the Teva UK Limited Communications team on +44(0)1977-628500, or email media.enquiries at tevauk.com.